We are happy to celebrate a major achievement by one of our members, Xiamen Innovax Biotech Co., Ltd., whose 9-valent HPV vaccine, Cecolin®9, has officially received regulatory approval from China’s National Medical Products Administration (NMPA)!
Jointly developed with Xiamen University, Cecolin®9 is China’ first domestically developed 9-valent HPV vaccine. This approval makes China the second country in the world, after the United States, with the capability to independently manufacture and supply such a vaccine.
Approved for females aged 9 to 45, Cecolin®9 offers broad protection against cervical cancer, a disease that continues to place a heavy burden on women, especially in LMICs. The vaccine is available in a two-dose regimen for girls aged 9–17 and a three-dose regimen for women aged 18–45, making it both flexible and accessible across different age groups so that no one is left behind.
With high production capacity, robust quality control, and a strong safety profile, Cecolin®9 is set to significantly expand access to HPV vaccination and reduce the global disease burden by preventing the most high-risk strains of HPV responsible for cervical cancer.
At DCVMN, we are proud of our members who continue to innovate and contribute to protecting public health in developing countries. Female-centered health too often remains under-prioritized globally, so the approval of Cecolin®9 is not just a scientific achievement, it is a powerful stride toward safeguarding the health and futures of girls and women.
Congratulations, Innovax! Your work brings us all one step closer to the WHO’s goal of eliminating cervical cancer worldwide.
